Apr 23, 2025
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2025 Digestive Disease Week (DDW) Annual Meeting
Apr 10, 2025
Mallinckrodt plc to Report Earnings Results for First Quarter 2025
Mar 13, 2025
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides 2025 Guidance
Mar 13, 2025
Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader
Mar 10, 2025
Mallinckrodt plc Reschedules Release of Fourth Quarter and Fiscal Year 2024 Financial Results to Thursday, March 13, 2025
Dec 02, 2024
Mallinckrodt Completes Divestiture of Therakos® Business
Nov 18, 2024
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Nov 14, 2024
Mallinckrodt to Present at Jefferies London Healthcare Conference
Nov 05, 2024
Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance
Oct 29, 2024
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at the American College of Gastroenterology (ACG) Annual Meeting
Oct 26, 2024
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at Kidney Week 2024
Oct 10, 2024
Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE(TM) DS Delivery System in U.S. Hospitals
Sep 17, 2024
Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect(TM) Injector
Aug 06, 2024
Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance
Aug 06, 2024
Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect(TM) Injector in the U.S.
Aug 05, 2024
Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million
Jun 05, 2024
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress
Mar 11, 2024
Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients
Mar 04, 2024
Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands
Mar 01, 2024
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect(TM) Injector